微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 58.17% | -2.82% | 1.45% | 57/160 | 22.89% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 57.34% | -7.63% | -1.74% | 62/160 | 33.26% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 58.35% | -5.07% | -2.53% | 54/160 | 51.37% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 59.87% | -9.36% | 0.02% | 55/160 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 59.86% | -12.02% | -3.57% | 56/160 | 32.75% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 62.08% | -10.56% | 0.99% | 52/160 | 38.61% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 61.47% | -15.14% | -6.94% | 52/160 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 66.05% | -4.37% | -2.91% | 46/160 | 53.57% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 68.03% | -0.1% | -1.98% | 44/160 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 69.4% | 3.13% | -4.19% | 43/160 | 21.79% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 72.44% | 15.78% | 4.88% | 37/160 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 69.07% | 18.37% | 1.42% | 47/160 | 55.07% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 68.1% | 9.53% | 1.2% | 40/160 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 67.29% | 8.81% | 7.55% | 45/160 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 62.57% | 12.69% | 7.24% | 47/160 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 58.35% | -16.31% | -6.16% | 63/160 | -143.08% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 62.17% | -15.67% | 0.53% | 51/160 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 61.84% | -18.36% | 11.38% | 51/160 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 55.52% | -26.5% | -20.36% | 53/160 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 69.71% | 2.9% | -5.44% | 40/160 | -1204.25% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 73.72% | 11.79% | -2.67% | 21/160 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 75.75% | 16.56% | 0.28% | 23/160 | 55.36% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 75.54% | 10.21% | 11.5% | 17/160 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 67.75% | 18.1% | 2.72% | 40/160 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 65.95% | 19.17% | 1.48% | 27/160 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 64.99% | 26.4% | -5.18% | 29/160 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 68.54% | 53% | 19.48% | 25/160 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 57.37% | 54.95% | 3.66% | 51/160 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 55.34% | 56.88% | 7.64% | 39/160 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 51.42% | 48.01% | 14.76% | 44/160 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 44.8% | 73.14% | 21.01% | 45/160 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 37.02% | 0.95% | 4.95% | 76/160 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 35.28% | -22.68% | 1.55% | 52/160 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 34.74% | -31.63% | 34.25% | 63/160 | 46.2% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 25.88% | -53.89% | -29.45% | 66/160 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 36.68% | -36.88% | -19.62% | 67/160 | 46.24% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 45.63% | -19.68% | -10.2% | 35/160 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 50.81% | -8.48% | -9.47% | 33/160 | 45.36% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 56.12% | 4.93% | -3.41% | 21/160 | 43.46% | 舒泰神 | 94.4% | 行业排名> |